Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Basic helix-loop-helix family member a9 (BHLHA9)
- Target
- BHLHA9
- Molecular classification
- Transcription factor, Basic helix-loop-helix protein
01
Overview
Basic helix-loop-helix family member a9 (BHLHA9) is a protein-coding gene whose product is a member of the basic helix-loop-helix (bHLH) superfamily of transcription factors. This protein contains conserved domains: a basic DNA-binding domain and a helix-loop-helix region essential for dimerization and interaction with other proteins. BHLHA9 is essential in embryonic limb development, functioning as a master regulator within a complex transcriptional network controlling limb morphogenesis. Its expression is spatially restricted to the distal mesenchyme of limb buds during mouse and zebrafish embryogenesis. Pathogenic mutations or copy number changes in BHLHA9 cause several congenital limb abnormalities, notably MSSD and split-hand/split-foot syndrome with long bone deficiency, confirming its critical role in limb patterning. No drugs or therapeutic modulators are known for this gene as of this date.
- Other names
- BHLHA9BHLHF42basic helix-loop-helix family member a9FingerinCCSPDClass A basic helix-loop-helix protein 9Class F basic helix-loop-helix factor 42class II basic helix-loop-helix protein
02
Mechanism of action
Not applicable; no drugs currently target BHLHA9.
03
Biological functions
Transcriptional regulationLimb developmentProtein dimerization/heterodimerizationDevelopmental morphogenesis
04
Disease associations
Congenital limb malformation syndromes, including: Syndactyly, mesoaxial synostotic, with phalangeal reduction (MSSD)Camptosynpolydactyly, complexSplit-hand/foot malformation with long bone deficiency (SHFLD3)
05
Safety considerations
Not applicable to therapy; safety issues relate to the risk of congenital limb defects from inherited or de novo loss-of-function or missense mutations in BHLHA9
06
Biomarkers
Pathogenic mutations or copy number variation affecting BHLHA9 can be used as genetic biomarkers for selecting or diagnosing patients with limb malformation syndromes, particularly MSSD and SHFLD3
Beyond the preview
Go deeper on Basic helix-loop-helix family member a9 (BHLHA9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Basic helix-loop-helix family member a9 (BHLHA9).